Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.11

-2.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (163)	4/13/1999 10:38:00 AM
From: LLCF	Read Replies (1) of 52153

<flattening out the valuation curve until the very end, where it grows very steeply.> < do you bet that this situation will perpetuate, or that sanity will return to valuations for patents and pipes?> Yes interesting... this [don't buy until approaved/profitable] type of approach would create opportunity at this "dislocation point". So subjects approaching this point are way too cheap, especially if they are ALL treated the same. My "twisted" comment reflected my thinking that it is self evident that a % of "patents and pipes" [catapillers] turn into butterflys. Maybe buy catapillers and play options on butterflys??? And how does all this fit with the fact that lots of these stocks have acted terribly apon boardering on profitability? Almost like there's a "kink" in the curve! DAK

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next